Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 109,800 shares, a drop of 33.8% from the October 15th total of 165,900 shares. Currently, 2.3% of the company’s shares are sold short. Based on an average trading volume of 65,200 shares, the days-to-cover ratio is currently 1.7 days.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday.

Brainstorm Cell Therapeutics Trading Up 7.1 %

NASDAQ:BCLI traded up $0.08 during midday trading on Friday, reaching $1.21. The company had a trading volume of 144,005 shares, compared to its average volume of 58,364. Brainstorm Cell Therapeutics has a 12-month low of $1.05 and a 12-month high of $11.89. The stock’s fifty day simple moving average is $2.59 and its 200-day simple moving average is $4.75.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.60). During the same period in the previous year, the firm posted ($4.05) earnings per share. Sell-side analysts anticipate that Brainstorm Cell Therapeutics will post -2.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.